Avexitide Phase 2 Signal Is Real But Underpowered: First-in-Class PBH Bet Hinges on Phase 3 Replication

Amylyx's GLP-1 Blocker Shows Strong Efficacy in Hypoglycemia

Amylyx's investigational GLP-1 blocker, avexitide, demonstrated promising results in treating low blood sugar in patients who have undergone weight loss surgery. In a study of patients with post-bariatric hypoglycemia, avexitide achieved a 55% reduction in the composite rate of level 2 and level 3 hypoglycemic events, surpassing analyst expectations. This positive outcome marks a significant turnaround for the company, which previously withdrew its ALS drug Relyvrio from the market after a Phase 3 trial failed to show efficacy.

• Amylyx's GLP-1 blocker, avexitide, achieved a 55% reduction in the composite rate of level 2 and level 3 hypoglycemic events in patients with post-bariatric hypoglycemia. This significant reduction in severe low blood sugar episodes exceeded analyst expectations, indicating a strong therapeutic effect for a condition that currently lacks effective treatments. The positive data provides a crucial step forward for patients suffering from this complication of weight loss surgery.
• The positive results for avexitide represent a 'redemption story' for Amylyx, following the company's decision two years prior to pull its ALS drug, Relyvrio, from the market due to a lack of efficacy in a Phase 3 trial. This new data for their GLP-1 blocker could re-establish investor confidence and provide a new direction for the company's pipeline, shifting focus towards metabolic disorders.
• The study specifically targeted patients experiencing post-bariatric hypoglycemia, a challenging condition characterized by recurrent episodes of low blood sugar after weight loss surgery. This patient group often faces significant quality of life issues and health risks. The success of avexitide in this population addresses an unmet medical need, offering a potential new therapeutic option where current treatments are limited.

Avexitide's Positive Outcomes in Post-Bariatric Hypoglycemia Trial

Recent clinical investigation into post-bariatric hypoglycemia (PBH) has yielded meaningful data across pharmacological, hormonal, and algorithmic intervention strategies. The following studies highlight diverse therapeutic approaches alongside their key safety and efficacy findings.

• Cholecystectomy Impact Study (The Impact of Cholecystectomy in Patients with Post-Bariatric Surgery Hypoglycemia) — Intervention: Acarbose. In this retrospective cohort of 131 PBH patients (29 with prior cholecystectomy), those with a history of cholecystectomy required significantly higher acarbose doses for symptom control (p = 0.046). Mixed meal tolerance testing further revealed elevated insulin levels at 60 and 90 minutes (p = 0.010 and p = 0.034, respectively), higher C-peptide levels at 60 minutes (p = 0.008), and greater glycemic variability (p = 0.049) in the cholecystectomy subgroup. No severe safety concerns were reported across the cohort.

• Semaglutide Case Report (Efficacy of Semaglutide in Reactive Hypoglycemia Related to Dumping Syndrome after Bariatric Surgery) — Intervention: Semaglutide (long-acting GLP-1 receptor agonist). In a 31-year-old female patient intolerant to metformin and unresponsive to acarbose, semaglutide reduced time-below-range (glucose <70 mg/dL) from 12% to 4% at 0.25 mg/week and to 1% at 0.5 mg/week. Symptomatic improvement was sustained for up to 8 months, with normalization of the daily glycemic profile and resolution of hypoglycemic episodes. The treatment was well tolerated.

• Glucagon Delivery System Study (Design and Clinical Evaluation of a Novel Low-Glucose Prediction Algorithm with Mini-Dose Stable Glucagon Delivery in Post-Bariatric Hypoglycemia) — Intervention: Mini-dose liquid glucagon (150 μg, later modified to 300 μg with an optional second dose), delivered via an automated closed-loop system integrating a Dexcom CGM, a Windows tablet running a postmeal hypoglycemia prediction algorithm, and an Omnipod pump. Across seven participants with PBH and a history of neuroglycopenia, the algorithm successfully identified impending postmeal hypoglycemia, with iterative system modifications yielding progressive improvements in glucose time above the 75 mg/dL threshold. Mini-dose glucagon was well tolerated, with no episodes of prolonged or severe hypoglycemia and no rebound hyperglycemia observed.

The Unmet Need in Post-Bariatric Hypoglycemia Treatment

Post-bariatric hypoglycemia (PBH) remains a clinically challenging condition due to its complex, incompletely understood pathophysiology and the absence of standardized diagnostic and therapeutic frameworks. The interplay of excessive GLP-1 secretion, nesidioblastosis, and increased glucose effectiveness has made it difficult to develop targeted, reliable treatment strategies.

• Absence of a diagnostic gold standard: No consensus exists on the optimal method for confirming PBH. CGM demonstrates a sensitivity and specificity of 90% and 50%, respectively, while the mixed meal tolerance test (MMTT) performs even less favorably at 33% and 40% — leaving clinicians without a reliable confirmatory tool and risking both under- and over-diagnosis.

• High burden of asymptomatic hypoglycemia: Hypoglycemia is predominantly asymptomatic, with CGM identifying nocturnal asymptomatic episodes in 70% of patients and daytime postprandial events in 25%. The mean daily duration of asymptomatic hypoglycemia exceeds 30 minutes, underscoring that clinical symptom reporting alone substantially underestimates disease burden.

• Unpredictable response to pharmacotherapy: Agents including diazoxide, acarbose, calcium channel blockers, and octreotide have demonstrated benefit, but individual response is highly variable, making it difficult to establish consistent, evidence-based treatment algorithms for this population.

• Surgical intervention as a last resort with incomplete efficacy: Patients refractory to dietary modification and medical therapy may require surgical reversal of Roux-en-Y gastric bypass (RYGB); however, outcomes remain mixed — only 45% of patients (6/11) achieved complete remission of PBH post-reversal, and a subset continued to experience RYGB-related symptoms despite intervention.

• Worsening prevalence over time: Time elapsed since the original bariatric procedure is positively associated with increased rates of both total PBH and nocturnal PBH, suggesting the condition can emerge or progress years post-operatively — complicating long-term surveillance and management planning.

Evolving Treatment Landscape for Post-Bariatric Hypoglycemia

The treatment landscape for post-bariatric hypoglycemia (PBH) has undergone meaningful expansion over the past several years, transitioning from near-exclusive reliance on dietary modification toward an increasingly pharmacologically diverse approach — though the evidence base remains nascent. A systematic review and meta-analysis drawing from 2,134 screened records identified 13 comparative studies (12 RCTs and one retrospective study), five single-intervention studies, and 15 case reports evaluating pharmacologic treatments for PBH. This growing body of literature reflects heightened clinical attention to PBH as a distinct post-surgical complication, yet the certainty of evidence across studies has been rated as very low, owing to small sample sizes, heterogeneous definitions of PBH, and imprecise effect estimates.

Among the pharmacological agents evaluated in comparative trials, anakinra and empagliflozin both demonstrated statistically significant reductions in hypoglycemia risk relative to placebo (RR: 0.29; 95% CI: 0.09–0.91 for both), while dasiglucagon has shown utility as a rescue agent. Single-intervention studies have reported that pasireotide and acarbose prevented hypoglycemia in all treated patients, and case report data have documented variable success with liraglutide, verapamil, and semaglutide. Of clinical note, patients with a prior cholecystectomy were found to require higher acarbose doses compared to those without this surgical history (p = 0.046), underscoring the importance of individualized treatment strategies based on patient-specific surgical context.

Despite these therapeutic advances, the field lacks an approved pharmacotherapy, and dietary modifications alongside continuous glucose monitoring (CGM) remain foundational management tools. CGM has emerged as a particularly valuable instrument for capturing postprandial glycemic excursions that inform individualized intervention strategies. The considerable heterogeneity across trials, wide confidence intervals, and inconsistent PBH definitions continue to preclude robust, generalizable conclusions. Adequately powered RCTs incorporating standardized PBH definitions, patient-centered outcome measures, and longer follow-up durations are urgently needed to translate these early signals into evidence-based therapeutic guidelines.

Avexitide's Promise: A Strategic Rebirth for Amylyx

The recent positive data for avexitide in post-bariatric hypoglycemia (PBH) marks a pivotal moment, not just for patients suffering from this debilitating condition, but also for the company behind it. PBH, a severe complication following weight loss surgery, currently lacks approved therapies, leaving patients with limited and often inadequate treatment options. Avexitide, a glucagon-like peptide-1 (GLP-1) antagonist, has demonstrated compelling efficacy in a Phase 2 study, significantly reducing hypoglycemic events and improving key metabolic parameters. This success validates the scientific premise of targeting the GLP-1 receptor to counteract hyperinsulinemic hypoglycemia, a mechanism supported by existing literature.

For the company, this development represents a crucial strategic turnaround. After the highly publicized withdrawal of its amyotrophic lateral sclerosis (ALS) drug, Relyvrio, following a failed Phase 3 trial, the company faced significant challenges to its pipeline and market standing. Avexitide's strong performance offers a clear path forward, allowing a strategic pivot into metabolic disorders and potentially restoring investor confidence. This could establish a new revenue stream and demonstrate the company's capability to bring innovative therapies to market, particularly in areas of high unmet need.

However, the journey ahead is not without its considerations. While the Phase 2 data is encouraging, the transition to larger, confirmatory Phase 3 trials will be critical. The history of drug development is replete with examples where Phase 2 success does not translate to Phase 3. Furthermore, the company's prior experience with AMX0035 (Relyvrio) involved intense regulatory scrutiny and public debate over its clinical effectiveness and high pricing. These factors suggest that future regulatory submissions for avexitide may face heightened examination, and careful consideration will be needed for market access and pricing strategies to ensure broad patient availability without reigniting past controversies. Ultimately, avexitide's potential to be a first-in-class treatment for PBH offers a beacon of hope, but its path to market will require robust clinical validation and astute strategic execution.